Guardant Health (GH)

Executive Summary

Guardant Health is a leading precision medicine company revolutionizing cancer care through its innovative blood-based diagnostic tests. The company's flagship product, Guardant360, is widely used for comprehensive genomic profiling in advanced solid tumors, while its Guardant Reveal test enables minimal residual disease detection for treatment monitoring. In 2024, Guardant received FDA approval for Shield, a blood test for colorectal cancer screening, marking a significant milestone in expanding liquid biopsy into early detection. The company's data-driven approach leverages a vast real-world evidence database to enhance test sensitivity and accelerate personalized therapies. With a robust commercial portfolio of eight approved products and strong adoption among oncologists, Guardant is well-positioned to capture a growing share of the multi-billion-dollar cancer diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Shield lung cancer screening indication65% success
• Q2 2026Medicare coverage determination for Shield colorectal cancer screening80% success
• Q4 2026Launch of next-generation MRD test for early-stage cancer monitoring70% success